Wednesday, July 8, 2026

biotech · Chronic Inducible Urticaria · Chronic Spontaneous Urticaria · JSPR

Jasper Therapeutics

Jasper Therapeutics is a biotech organization headquartered in Redwood City, USA. It trades on NYSE under ticker JSPR. Primary therapeutic focus areas include Chronic Inducible Urticaria, Chronic Spontaneous Urticaria, a

Redwood City, CA, US HQ
44 Employees
Public company Type
JSPR · NYSE Ticker
Company details
Status
Public
HQ
Redwood City, CA, US
Employees
44
Programs
13
Drugs
13
Patents
1
Clinical program

Nicotine patch

Phase 3 · small molecule · Nicotine Dependence

Nicotine patch for Nicotine Dependence is a Phase 3 program (small_molecule) at Jasper Therapeutics with 1 ClinicalTrials.gov record(s).

← All Jasper Therapeutics projects Phase 3 small molecule active

Internal code 2016120049

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Jasper Therapeutics
Phase
Phase 3
Modality
small_molecule
Indication
Nicotine Dependence
Status
active
Trials
1